Literature DB >> 22968545

Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar.

Dirk Deleu1, Danial Mir, Ahmed Al Tabouki, Rim Mesraoua, Boulenouar Mesraoua, Naveed Akhtar, Hassan Al Hail, Atlantic D'souza, Gayane Melikyan, Yahia Z B Imam, Yasir Osman, Osama Elalamy, Tageldin Sokrab, Sadaat Kamran, Francisco Ruiz Miyares, Faiza Ibrahim.   

Abstract

No published epidemiologic data on multiple sclerosis (MS) in Qatar exist. Our objectives were to determine the prevalence, demographics and clinical characteristics of MS in the Middle Eastern country of Qatar. We analyzed data for Qatari MS patients fulfilling the McDonald diagnostic criteria. A total of 154 patients fulfilled the inclusion criteria. On 31 April 2010, the crude prevalence of MS in Qatar was 64.57 per 100,000 inhabitants (95% CI: 58.31-70.37). The female-to-male ratio was 1.33:1. A positive family history was found in 10.4% of included MS patients. We conclude that Qatar is now a medium-to-high risk area for MS, with some important differences in clinical characteristics as compared to other countries in the region.

Entities:  

Keywords:  Arabian peninsula; MRI; Qatar; epidemiology; multiple sclerosis; prevalence

Mesh:

Year:  2012        PMID: 22968545     DOI: 10.1177/1352458512459291

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  16 in total

1.  Distinct HLA class I and II genotypes and haplotypes are associated with multiple sclerosis in Bahrain.

Authors:  Moudi Al-Nashmi; Safa Taha; Abdel Halim Salem; Isa Alsharoqi; Moiz Bakhiet
Journal:  Biomed Rep       Date:  2018-10-24

2.  Clinical Profile and the Extent of Disability in Multiple Sclerosis Patients in Madinah, Saudi Arabia.

Authors:  Esraa Q Alsaedi; Marwa Q Alsaedi; Farah A Mansuri
Journal:  Cureus       Date:  2022-06-11

3.  Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countries.

Authors:  Mohammed Aljumah; Raed Alroughani; I Alsharoqi; Saeed A Bohlega; Maurice Dahdaleh; Dirk Deleu; Khaled Esmat; Ahmad Khalifa; Mohammad A Sahraian; Miklós Szólics; Abdulrahman Altahan; Bassem I Yamout; Peter Rieckmann; Abdulkader Daif
Journal:  Mult Scler Int       Date:  2013-12-17

4.  Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka.

Authors:  S M K Gamage; I Wijeweera; S B Adikari; Katharina Fink; Jan Hillert; Anna Fogdell-Hahn; H M A Sominanda
Journal:  Mult Scler Int       Date:  2018-02-28

5.  Magnitude and concurrence of anxiety and depression among attendees with multiple sclerosis at a tertiary care Hospital in Oman.

Authors:  Abdullah Al-Asmi; Salim Al-Rawahi; Zahir Saif Al-Moqbali; Yahya Al-Farsi; Musthafa M Essa; May El-Bouri; Roopa P Koshy; Arunodaya R Gujjar; P C Jacob; Abeer Al-Hodar; Samir Al Adawi
Journal:  BMC Neurol       Date:  2015-08-05       Impact factor: 2.474

Review 6.  Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring.

Authors:  Raed A Alroughani; Hany M Aref; Saeed A Bohlega; Maurice P Dahdaleh; Imed Feki; Mohammed A Al Jumah; Muhammad Z Al-Kawi; Salam F Koussa; Mohamad A Sahraian; Isa A Alsharoqi; Bassem I Yamout
Journal:  BMC Neurol       Date:  2014-02-12       Impact factor: 2.474

7.  ZFAT gene variant association with multiple sclerosis in the Arabian Gulf population: A genetic basis for gender-associated susceptibility.

Authors:  Sonia Bourguiba-Hachemi; Tebah K Ashkanani; Fatema J Kadhem; Wassim Y Almawi; Raed Alroughani; M Dahmani Fathallah
Journal:  Mol Med Rep       Date:  2016-08-30       Impact factor: 2.952

8.  Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study.

Authors:  Sherif M Hamdy; Maged Abdel-Naseer; Nevin M Shalaby; Alaa N Elmazny; Ahmed A Nemr; Amr Hassan; Mohamed I Hegazy; Husam S Mourad; Nirmeen A Kishk; Mona A Nada; Ahmed Abdelalim; Amr M Fouad; Hatem S Shehata
Journal:  Neuropsychiatr Dis Treat       Date:  2017-07-18       Impact factor: 2.570

9.  Increasing prevalence of familial recurrence of multiple sclerosis in Iran: a population based study of Tehran registry 1999-2015.

Authors:  Sharareh Eskandarieh; Narges Sistany Allahabadi; Malihe Sadeghi; Mohammad Ali Sahraian
Journal:  BMC Neurol       Date:  2018-02-07       Impact factor: 2.474

10.  Prevalence and Incidence of Multiple Sclerosis in Tehran, Iran.

Authors:  Sharareh Eskandarieh; Pouria Heydarpour; Seyedeh-Robab Elhami; Mohammad Ali Sahraian
Journal:  Iran J Public Health       Date:  2017-05       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.